Pearce Mendoza (mousebra8)

Five patients (26%) had acute hospital stays coinciding with or within three months post-completion of their CRT intervention. Treatment interruptions in CRT occurred for two patients (11%). Eighty-six percent (70 out of 81) of the surveys administered during CRT were flagged, and 87% (61 out of 70) of these flagged surveys received action from a nurse or physician within four days. Similarly, during the first three months following CRT, 55% (47 out of 85) of surveys were flagged, and 60% (28 out of 47) of these flagged surveys prompted a response within seven days. Ninety-two percent of patients reported always having easy access to the survey, but 58% considered them excessively long or overly frequent. In each of the measured periods, no statistically considerable change was found in any of the PROMIS domains. Symptom self-reporting using a web-based interface (WBI) is demonstrably achievable and well-received by patients undergoing definitive chemoradiation. Common survey fatigue can be countered by enhancing the patient-centeredness of the WBI and empowering patients to choose which symptoms they report. High patient satisfaction accompanies the feasibility of symptom self-reporting via a WBI during definitive chemoradiation. Survey fatigue is often reported, and its effects can be lessened by building a more patient-focused WBI system that gives patients a choice about the symptoms they report. Brain metastases (BMs) are a substantial cause of both morbidity and mortality. For locally advanced non-small cell lung cancer (LA-NSCLC), guidelines do not advocate for brain surveillance. We examine the rate of BMs, their emergence after definitive chemo-radiotherapy (CRT), the way they manifest, and how they are addressed. Records pertaining to LA-NSCLC patients undergoing CRT treatment from 2013 to 2020 were scrutinized. Descriptive statistics characterized the population, with the Kaplan-Meier method providing estimates for time to BM. The impact of symptoms on outcomes was further analyzed via Fisher's exact tests and the Wilcoxon rank-sum tests. From a cohort of 219 patients reviewed, a subgroup of 96 patients exhibited squamous cell carcinoma, 88 exhibited adenocarcinoma, and 35 exhibited large cell/not otherwise specified (LC/NOS). Among the 39 patients (178%) who developed bowel movements, 35 (90%) exhibited symptoms, and 4 (10%) were asymptomatic. Concerning BM rates, LC/NOS reached a peak of 343%, while adenocarcinoma showed a rate of 239%. Two years encompassed ninety percent of all observed BMs. Symptomatic patients, in contrast to asymptomatic patients, had an alternative treatment strategy, administered to 40% of them. A noteworthy statistical difference emerged, with a p-value of 0.04. Patients exhibiting symptoms were substantially more prone to necessitate hospitalization (657% versus 0%). The experimental group experienced a substantial increase in both craniotomies (257% vs 0%) and steroid treatment (914% vs 0%) compared to the control group, along with a noteworthy difference in the .02 event rate. A profoundly statistically significant finding emerged, with a p-value less than .001. Symptom presence correlated with a greater cumulative volume of bowel movements in patients (4 cm versus 0.24 cm). , Group one exhibited a median greatest axial dimension of 218 cm, whereas group two displayed a significantly smaller dimension (0.52 cm), signifying a difference of statistical significance (p < 0.001). < .001). Our analysis revealed a high frequency of BMs, particularly in cases categorized as LC/NOS and adenocarcinoma histology NSCLC. The preponderant part of the group presented symptoms. Magnetic resonance imaging brain surveillance after CRT is warranted for patients with elevated BM risk, according to these results. BMs were found at a high frequency, particularly among LC/NOS and adenocarcinoma histology NSCLC patients. The sympto